On April 3, 2026, in Waltham, Massachusetts, Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced the approval of stock options by its independent Compensation Committee of the Board of Directors. The options allow for the purchase of 70,200 shares of common stock as equity awards under the 2018 Equity Inducement Plan. Five non-executive employees received these options on April 1, 2026. The grants were crucial in securing the employment of these individuals at Spyre, aligning with Nasdaq Listing Rule 5635(c)(4). Spyre is focused on developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases.